Apruritic Scabies Presenting on IL-31 Blockade with Nemolizumab: A Case Report

Bindi Gaglani; Elaine Agius; C. Smith; Richard Woolf; Andrew Pink

doi:10.1093/ced/llag309

Apruritic Scabies Presenting on IL-31 Blockade with Nemolizumab: A Case Report

Clicks: 24

ID: 321937

2026

Free PDF

Article Quality & Performance Metrics

Overall Quality

Not rated

Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.

Reader Engagement Steady Performance

6.9 /100

24 views

21 readers

AI Quality Assessment

Not analyzed

Readership in this journal

Steady

Ranked #74 of 245 articles by views in clinical and experimental dermatology

Mint this article as an NFT

Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required

Sign in to mint

Abstract

EN
- Turkish
- Spanish
- Portuguese
- Arabic
- Chinese
- French
- German
- Indonesian
- Russian
- Thai

Nemolizumab is, a humanized IgG2 monoclonal antibody that inhibits interleukin-31 signaling by binding to the interleukin-31 RA receptor alpha and a first in class IL-31 receptor A antagonist, has proven been effective at reducing pruritis and objective skin signs ion atopic dermatitis and nodular prurigo. in reducing pruritus in patients with atopic dermatitis. However, by suppressing itch, nemolizumab may also delay the presentation of pruritic skin conditions such as scabies, potentially complicating diagnosis. This case highlights a patient who developed a late presentation of scabies while on long-term nemolizumab therapy. The delayed pruritic response to scabies, likely due to the suppression of itch by nemolizumab, underscores the need for thorough dermatological evaluation

Abstract Quality Issue: This abstract appears to be incomplete or contains metadata (112 words). Try re-searching for a better abstract.

Reference Key	openalex_W7169831706 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors	Bindi Gaglani, Elaine Agius, C. Smith, Richard Woolf, Andrew Pink Are you one of these authors? Claim your profile
Journal	clinical and experimental dermatology
Year	2026
DOI	10.1093/ced/llag309 Searching for DOI...
URL	https://doi.org/10.1093/ced/llag309 https://doi.org/10.1093/ced/llag309
Keywords	Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

Login to comment Register

No comments yet. Be the first to comment on this article.

Which of these authors are you? Claiming connects that author profile to your account once an admin has checked it.

Bindi Gaglani

Elaine Agius

C. Smith

Richard Woolf

Andrew Pink

How can we tell it is you? (optional)

An admin reviews every claim, and we email you when it is decided.

Claiming needs an account. After you pick your name you will be asked to sign in (no password: we email you a link), and your claim is sent as soon as you are back.